Lantern Pharma Shares Surge Over 30% as FDA Clears IND Application for STAR-001 in Pediatric Clinical Trial

ByAInvest

Monday, Mar 30, 2026 4:20 am ET1min read

Lantern Pharma's shares surged 30% to $1.45 after the FDA cleared the IND application for STAR-001 in a planned Phase 1 pediatric clinical trial. The firm is scheduled to report its fiscal Year 2025 financial results today. Lantern Pharma focuses on oncology drugs and has a pipeline of investigational products including LP-300, LP-184, and LP-284. The planned trial for STAR-001 will evaluate the compound in pediatric patients with relapsed or refractory CNS malignancies.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Lantern Pharma Shares Surge Over 30% as FDA Clears IND Application for STAR-001 in Pediatric Clinical Trial

Stay ahead of the market.

Comments

AInvestPRO

AInvest

AInvest
PRO